The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review

BACKGROUND: Monoclonal antibodies (mAbs) approved for use as add-on therapy in patients with severe asthma target the underlying pathogenesis of asthma. MAIN BODY: Omalizumab binds immunoglobulin E (IgE), thereby inhibiting its interaction with the high-affinity IgE receptor and reducing the quantit...

Descripción completa

Detalles Bibliográficos
Autores principales: Matucci, Andrea, Vultaggio, Alessandra, Danesi, Romano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097430/
https://www.ncbi.nlm.nih.gov/pubmed/30115042
http://dx.doi.org/10.1186/s12931-018-0859-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097430/
https://www.ncbi.nlm.nih.gov/pubmed/30115042
http://dx.doi.org/10.1186/s12931-018-0859-z

Ejemplares similares